“Sean Lyden MD, Professor and Chairman Vascular Surgery Cleveland Clinic on the mainstage at ISET 2024”
News
SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
– Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025
– Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs
– Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and is eligible to receive up to $275 million of milestone payments and mid-to-high single-digit royalties
SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors
Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma
VIPER-101 is an autologous, CD5 knock-out CAR-T therapy for the treatment of T-cell lymphoma
Initiating first-in-human Phase 1 trial in H1 of 2024
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
Palvella Received $5 Million Upfront Payment
QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with Microcystic Lymphatic Malformations
U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ rapamycin for the Treatment of Microcystic Lymphatic Malformations in November 2023